Eton Pharmaceuticals plans ASN-001 NDA submission in 2H 2027 after infantile hemangioma Phase II/III data

• Eton Pharmaceuticals licensed U.S. rights to late-stage ASN-001, a topical timolol gel for moderate superficial infantile hemangiomas.
• Clinical results were already presented from a completed Phase II/III trial, showing better lesion clearance than placebo.
• A bioavailability bridging study is planned to support an NDA filing in 2H 2027, targeting a 2028 launch.
• Management flagged 20,000 to 30,000 potential annual patients, positioning ASN-001 as a possible top portfolio revenue driver.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-025781), on August 05, 2026, and is solely responsible for the information contained therein.